{{.infobox .infobox-gene}}
| Symbol | SLC22A6 |
| Full Name | Solute Carrier Family 22 Member 6 (Organic Anion Transporter 1) |
| Chromosome | 11q13 |
| NCBI Gene ID | 6579 |
| OMIM | 607482 |
| Ensembl ID | ENSG00000197905 |
| UniProt ID | O15259 |
| Associated Diseases | Renal toxicity, Urate transport disorders |
The SLC22A6 gene encodes Organic Anion Transporter 1 (OAT1), a critical membrane protein primarily expressed in the kidney proximal tubules. OAT1 mediates the uptake of a wide range of organic anions from blood into renal tubular cells, playing a fundamental role in the renal excretion of drugs, toxins, and endogenous metabolites [1].
While OAT1 is predominantly studied in the context of renal pharmacology and toxicology, its function has important implications for neurodegeneration through its role in clearing neurotoxic compounds from circulation and maintaining systemic metabolite homeostasis [2].
OAT1 belongs to the SLC22 family of organic cation and anion transporters. It operates as a tertiary active transporter, using the inward gradient of dicarboxylates (particularly α-ketoglutarate) as a driving force. The dicarboxylate gradient is maintained by the Na⁺/dicarboxylate cotransporter (NaDC3), while the actual OAT1 transport is facilitated by exchange of organic anions with intracellular α-ketoglutarate [3].
OAT1 has an exceptionally broad substrate specificity, transporting:
The ability of OAT1 to transport kynurenic acid and other neuroactive metabolites is particularly relevant to neurodegeneration, as these compounds can be neurotoxic at high concentrations [5].
SLC22A6 is predominantly expressed in the kidney, specifically in the proximal tubule epithelial cells of the cortex and outer medulla. Expression is localized to the basolateral membrane of tubular cells, where it interfaces with peritubular capillaries. Minor expression has been detected in other tissues including the liver and brain, though at significantly lower levels [6].
OAT1's role in clearing organic anions from circulation has important implications for brain health. Several neurotoxic compounds that accumulate in neurodegenerative diseases are substrates for OAT1:
OAT1 is a major urate transporter in the kidney. Epidemiological studies have shown that higher serum urate levels are associated with reduced risk of Parkinson's disease and slower disease progression. This suggests that OAT1-mediated urate handling may influence neurodegenerative processes [10].
OAT1 transports several drugs that can cause neurotoxicity, including certain antivirals and chemotherapy agents. Impaired OAT1 function may alter the clearance of these compounds, potentially increasing their neurotoxic potential [11].
OAT1 is a key determinant of drug-induced renal toxicity. Its expression and function can be modulated by various conditions, including:
Reduced OAT1 function in these conditions can lead to accumulation of toxic compounds, including those that may affect the brain [12].
While SLC22A6 mutations are not directly linked to neurological disorders, the transporter's role in clearing neurotoxic metabolites suggests it may be a modifier of neurodegeneration risk. Reduced OAT1 function could contribute to the accumulation of neurotoxic compounds in conditions involving impaired renal function [13].
OAT1 is an important pharmacological target. Probenecid and cefepime are known OAT1 inhibitors that can alter the renal clearance of other drugs. Understanding OAT1 function is crucial for:
Organic anion transporters: their roles in drug disposition and toxicity (PMID: 15578787). ↩︎
Kidney disease and cognitive impairment (PMID: 20623764). ↩︎
OAT1 substrate specificity and drug interactions (PMID: 15994491). ↩︎
Kynurenic acid in neurodegenerative diseases (PMID: 19112869). ↩︎
Kynurenine pathway in Alzheimer's disease (PMID: 25425147). ↩︎
Uremic toxins and cognitive dysfunction (PMID: 24226062). ↩︎
Serum urate and Parkinson's disease risk (PMID: 19126594). ↩︎
Chronic kidney disease and neurodegeneration (PMID: 25245485). ↩︎